A Case of Probable Empagliflozin-Induced Psoriasis in a Patient with Diabetic Kidney Disease

Introduction: Drug-induced skin eruptions, including Psoriasiform eruptions may be encountered in clinical practice. The pattern of Psoriasis induced after drug exposure may vary from localized plaques, diffuse erythroderma, palmoplanta variants or nail disease. No current clinical criteria can reliably distinguish drug-induced psoriasis from conventional psoriasis. We present the case of 66 year-old black woman with type 2 DM , CKD & CHF started on Jardiance 10mg., The patient developed pruritus, followed by eruption of plaques and in palms, soles and erythroderma of legs, abdomen and face. Therapy with steroids & UV light, and cessation of Empagliflozin led to resolution. Case Description: A 66- year-old black woman with CKD stage 3, serum creatinine of 2.9mg/dl, eGR of 38 ml/min due to type 2 DM presented to renal clinic with a 7- week history of diffuse, itchy scaly rash and plaques affecting the hands, soles legs, trunk, back and face(Fig ! &2) without inving mouth, eyes or oral cavity.after starting empagliflozin 10mg daily for CKD. . Her medications included Empagliflozin started in February 2025, Carvedilol Furosemide &. Losartan. A diagnosis of likely drug-induced psoriasis was made and Empagliflozin was stopped. The patient was prescribed diphenhydramine for itching and clobetasol cream apllied twice daily to scaly lessions on affected areas. Discussion: SGLT-2 agents like have been shown to have salutary cardio-renal benefits in patients with CKD, i[1]. However some studies have described skin eruptions complicating use of these agents, such as uritticaria, erythema, atopic dermatitis.[2]. Two prior cases of psoriatic skin eruptions have been described with Dapagliflozin[3,4] . Our case is unique in that it occured with Empagliflozin, in a patient with no prior history of psoriasis. WE present the first case of Empagliflozin-induced psorisis in CKD patient. One study suggested no SGLT-2 had no impact on f psoriasis [5]